Table 1.
Patient characteristics.
| Baseline | All PAD Patients (n = 139) | Unlikely SI (n = 106) |
Probable/Possible SI (n = 33) |
p-Value |
|---|---|---|---|---|
| Age (years), mean ± SD | 66.4 ± 9.9 | 68.1 ± 9.7 | 60.8 ± 8.7 | 0.001 |
| Female Sex, n (%) | 38 (27) | 28 (26) | 10 (30) | 0.66 |
| Current smoker, n (%) | 43 (31) | 30 (28) | 13 (39) | 0.28 |
| Diabetes, n (%) | 48 (35) | 41 (39) | 7 (21) | 0.09 |
| HbA1c [%] | 6.19 ± 1.01 | 6.23 ± 10.7 | 6.07 ± 0.87 | 0.86 |
| Hypertension, n (%) | 122 (88) | 91 (86) | 31 (94) | 0.31 |
| Chronic Kidney disease (CKD), n (%) | 84 (60) | 73 (69) | 18 (55) | 0.14 |
| Stage 2 | 54 (64) | 44 (42) | 12 (36) | 0.69 |
| Stage 3 | 25 (18) | 21 (20) | 5 (15) | 0.62 |
| Stage 4 | 5 (6) | 8 (8) | 1 (3) | 0.67 |
| Stage 5 | 0 (0) | 0 (0) | 0 (0) | |
| Severity of PAD (Fontaine stage) | ||||
| I, n (%) | 49 (35) | 40 (38) | 9 (27) | 0.3 |
| II a, n (%) | 27 (19) | 18 (17) | 9 (27) | 0.21 |
| II b, n (%) | 43 (31) | 32 (30) | 11 (33) | 0.83 |
| III, n (%) | 8 (6) | 7 (7) | 1 (3) | 0.68 |
| IV, n (%) | 12 (9) | 9 (8) | 3 (9) | 0.99 |
| Creatinine, [µmol/L] | 109.30 ± 87.40 | 118.10 ± 99.40 | 85.30 ± 28.15 | 0.03 |
| eGFR [mL/min/1.73 m2] | 67.87 ± 21.12 | 69.25 ± 22.14 | 77.52 ± 15.53 | 0.07 |
| Total Cholesterol [mmol/L] | 4.50 ± 1.23 | 4.35 ± 1.19 | 4.89 ± 1.28 | 0.04 |
| HDL Cholesterol [mmol/L] | 1.19 ± 0.36 | 1.22 ± 0.38 | 1.12 ± 0.29 | 0.22 |
| Non-HDL [mmol/L] | 3.28 ± 1.26 | 2.69 ± 1.55 | 3.77 ± 1.25 | <0.001 |
| LDL Cholesterol [mmol/L] | 2.79 ± 1.18 | 2.62 ± 1.15 | 3.22 ± 1.14 | 0.01 |
| Triglycerides [mmol/L] | 2.11 ± 1.34 | 2.00 ± 1.35 | 2.39 ± 1.29 | 0.13 |
| ALAT [U/L] | 24.12 ± 17.40 | 22.70 ± 18.17 | 27.25 ± 15.10 | 0.06 |
| ASAT [U/L] | 25.21 ± 17.02 | 23.36 ± 17.26 | 29.31 ± 16.22 | 0.06 |
| Creatine Kinase [U/L] | 106.70 ± 109.10 | 102.40 ± 113.50 | 114.40 ± 97.78 | 0.30 |
Baseline characteristics for the general population (n = 139) and in regard to the probability of statin intolerance (SI). PAD: Peripheral artery disease.